TrumpRx Slashes Drug Prices 80%+
The TrumpRx program launched with dramatic prescription drug discounts: [Ozempic reduced from $1,028/month to $199, Wegovy from $1,349 to $25, and insulin from $250 to $25](). The program uses 'most favored nation' pricing pegged to lowest prices in peer nations and allows [direct manufacturer purchases via digital coupons, bypassing traditional insurance middlemen](). Major pharmaceutical firms including Pfizer, Lilly, Novo, and AstraZeneca are participating.
- The TrumpRx program is the public-facing result of a May 2025 executive order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which aimed to align U.S. drug prices with the lowest prices in other developed nations. This policy was a revival of a similar "most-favored nation" executive order from President Trump's first term in 2020, which was legally challenged and never implemented. - As an incentive for pharmaceutical companies to participate, the Trump administration offered a three-year exemption from potential tariffs on imported pharmaceuticals and their active ingredients. By January 2026, 15 out of 17 major pharmaceutical companies initially contacted by the administration had agreed to join the program. - The program's direct-to-consumer model is designed to circumvent pharmacy benefit managers (PBMs), the intermediaries who negotiate drug prices between manufacturers and insurers and often retain a portion of the rebates. - The TrumpRx.gov website acts as a portal, not a direct seller of drugs. It provides consumers with digital coupons or directs them to the manufacturers' websites to purchase medications at the discounted cash price. - Currently, purchases made through TrumpRx are only available to cash-paying patients and do not apply toward insurance deductibles. The administration has proposed "The Great Healthcare Plan" which, if passed by Congress, would allow these purchases to be covered by health plans. - In addition to the drugs mentioned in the summary, other examples of price reductions include Sanofi's blood thinner Plavix from $756 to $16 and Novartis's multiple sclerosis drug Mayzent from $9,987 to $1,137. - As part of the agreements, several participating drugmakers, including Bristol Myers Squibb, GSK, and Merck, have also committed to donating tons of active pharmaceutical ingredients for critical medications like the blood thinner Eliquis and antibacterial treatments to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). - Critics of the 'most favored nation' policy argue that it could lead to drug manufacturers delaying new drug launches in lower-priced countries to avoid setting a low benchmark, or creating country-specific formulations to complicate price comparisons.
